Pharma-Bio Serv (PBSV) Receivables - Net (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Receivables - Net for 17 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net fell 48.62% year-over-year to $2.7 million; the trailing twelve-month figure through Apr 2026 stood at $2.7 million (down 48.62% YoY), and the FY2025 full-year result was $5.3 million, changed 0.0% from the prior year.
• Receivables - Net improved to $2.7 million in Q2 2026 per PBSV's latest filing, from $2.7 million in the prior quarter.
• Across five years, Receivables - Net topped out at $5.5 million in Q2 2022 and bottomed at $2.0 million in Q3 2025.
• Historically, Receivables - Net has averaged $4.1 million across 5 years, with a median of $4.7 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Receivables - Net jumped 858.17% in 2022, then tumbled 61.97% in 2025.
• Over 5 years, Receivables - Net stood at $5.0 million in 2022, then fell by 20.91% to $3.9 million in 2023, then tumbled by 36.29% to $2.5 million in 2024, then fell by 5.98% to $2.4 million in 2025, then advanced by 15.37% to $2.7 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $2.7 million, $2.7 million, and $2.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.